Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges

• Main Authors: Mehdi Najar, Fatima Bouhtit, Rahma Melki, Hassan Afif, Abdellah Hamal, Hassan Fahmi, Makram Merimi, Laurence Lagneaux
• Format: Article
• Language: English
• Published: MDPI AG 2019-05-01
• Series: Journal of Clinical Medicine
• Subjects: immunity; therapy; mesenchymal stromal cells; immunomodulation; licensing; extracellular vesicles
• Online Access: https://www.mdpi.com/2077-0383/8/5/626

Stem cells have been the focus of intense research opening up new possibilities for the treatment of various diseases. Mesenchymal stromal cells (MSCs) are multipotent cells with relevant immunomodulatory properties and are thus considered as a promising new strategy for immune disease management. To enhance their efficiency, several issues related to both MSC biology and functions are needed to be identified and, most importantly, well clarified. The sources from which MSCs are isolated are diverse and might affect their properties. Both clinicians and scientists need to handle a phenotypic-characterized population of MSCs, particularly regarding their immunological profile. Moreover, it is now recognized that the tissue-reparative effects of MSCs are based on their immunomodulatory functions that are activated following a priming/licensing step. Thus, finding the best ways to pre-conditionate MSCs before their injection will strengthen their activity potential. Finally, soluble elements derived from MSC-secretome, including extracellular vesicles (EVs), have been proposed as a cell-free alternative tool for therapeutic medicine. Collectively, these features have to be considered and developed to ensure the efficiency and safety of MSC-based therapy. By participating to this Special Issue “Mesenchymal Stem/Stromal Cells in Immunity and Disease”, your valuable contribution will certainly enrich the content and discussion related to the thematic of MSCs.